IMVARIA helps patients with interstitial lung disease and idiopathic pulmonary fibrosis

MedTech Alum ‘21 IMVARIA brings artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious lung diseases. Fibresolve and ScreenDx are the first FDA-authorized tools in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). ScreenDx uses AI to automatically analyze medical data for findings suggestive of ILD while Fibresolve is an AI biomarker that serves as an adjunct in the diagnosis of IPF. Watch below as patients explain how IMVARIA’s technology impacted their journeys.

Laura Feldman was initially diagnosed with IPF. But Fibresolve’s noninvasive digital biomarker solution did not support this diagnosis, prompting her to seek a second opinion. To her great relief, she discovered that she did not have that specific form of ILD, leading to a significantly different treatment path. Since IPF typically requires long-term oral antifibrotic therapy, Fibresolve’s support—along with updated clinical insights—helped her avoid unnecessary treatment and explore more suitable options for her condition.

Lung fibrosis patient Nick Mascia faced significant challenges in obtaining a diagnosis. With the support of Fibresolve, he was able to navigate the process and finally receive clarity. In his own words, Nick shares how Fibresolve played a crucial role in his journey. He was especially excited about AI’s involvement in his care, expressing enthusiasm for its potential and the non-invasive nature of the approach.

Last year, IMVARIA helped another patient finally receive a diagnosis after years of searching—he was on his fourth doctor in so many years. With a clear diagnosis, he was able to begin treatment. Based on his older medical data, if Fibresolve had been available back then, it might have helped identify his condition nearly seven years earlier—potentially before he had lost half of his lung function.

IMVARIA’s AI-powered tools are reshaping the way serious lung diseases are detected and diagnosed, giving patients like Laura, Nick, and many others a clearer path forward. By integrating cutting-edge technology with clinical expertise, IMVARIA is not only improving diagnostic accuracy but also transforming patient outcomes. Learn more about IMVARIA.